News
Public · Published
Merck & Co., Inc. (MRK) FDA Sets April 22, 2027 Action Date For Two HIV Drug Applications
The FDA accepted two supplemental New Drug Applications for Merck's approved HIV treatment IDVYNSO and set April 22, 2027, as the target action date for both. Merck also plans to present HIV portfolio and pipeline data, including Phase 3 subgroup analyses, at HIV Glasgow 2026, Nov. 8–11.
Published:
Updated:
What happened
The FDA accepted two supplemental New Drug Applications for Merck’s approved HIV treatment IDVYNSO and set April 22, 2027, as the target action date for both. Merck also plans to present HIV portfolio and pipeline data, including Phase 3 subgroup analyses, at HIV Glasgow 2026, Nov. 8–11.
Confirmed
Global impact / market context
Acceptance means the FDA will review the additional-use applications, not that it has approved them. A favorable decision could expand IDVYNSO’s permitted use and potential sales, while a delay or rejection would limit that opportunity; the article provides no expected revenue or decision outcome.
Analyst inference
This is a mid-cycle update: IDVYNSO is already approved in the United States for virologically suppressed adults, while the supplemental applications and pipeline programs remain under evaluation. The scheduled presentations may add clinical detail, but no results or commercial impact are disclosed.
Analyst inference
What to watch
- Watch for FDA decisions on both applications by the April 22, 2027 target date; acceptance starts review but does not establish approval or expanded use. Confirmed
- Merck’s HIV Glasgow presentations are scheduled for Nov. 8–11, 2026; reported subgroup analyses could clarify clinical evidence, but no results are provided yet. Confirmed
- Once-monthly HIV prevention remains in Phase 3 trials, meaning later-stage testing; efficacy and safety findings could shape its prospects, but none are reported here. Confirmed
Evidence
- Original source link unavailable